YORK medical company Tissue Regenix has set up a new subsidiary in the United States.

The business, which has developed a patented process to "wash" animal organs, such as heart valves, of DNA, enabling them to be implanted into humans and grow into a working part of the human body, has made the move to target the US's growing regenerative medicine market.

The business, based at York Science Park, has appointed Greg Bila, of Kinetic Concepts Inc (KCI) as president of Tissue Regenix USA. Mr Bila’s recent career at KCI has spanned a number of sales and marketing roles and brings over 20 years’ experience in pharmaceutical and medical device fields.

Antony Odell, managing director of Tissue Regenix, said: “This is a significant step in the development of Tissue Regenix. It is an excellent signal of the strength of Tissue Regenix’s proposition that we can attract people of Greg’s calibre and experience, we look forward to advancing our plans in the United States with him at the helm.

“The United States presents an opportunity to establish our platform dCELL technology in a market potentially worth hundreds of millions of dollars.”

Greg Bila, president of Tissue Regenix USA added: “I am excited to be able to join Tissue Regenix at the beginning of its expansion into the United States. Tissue Regenix’s dCELL technology will be a welcome offering for the treatment of number of diseases and the potential indications are attractive.”